Intest Res.  2022 Jul;20(3):342-349. 10.5217/ir.2021.00046.

A nationwide analysis on the influence of obesity in inflammatory bowel disease hospitalizations

• Dahiya DS
• Kichloo A
• Wani F
• Singh J
• Solanki D
• Shaka H

• KMID: 2531988
• DOI: http://doi.org/10.5217/ir.2021.00046

Abstract

Background/Aims
Proinflammatory cytokines released from adipocytes can influence the development, progression, and treatment of inflammatory bowel disease (IBD), and may be associated with worse clinical outcomes.
Methods
For 2016–2018, we analyzed data from the Nationwide Inpatient Sample to identify adult (≥18 years) hospitalizations with a primary discharge diagnosis of IBD. The study sample was divided based on the presence or absence of obesity. The primary outcomes included inpatient mortality, while the secondary outcomes consisted of system-based complications and disease implications on the United States healthcare system.
Results
We identified 282,005 hospitalizations of IBD from 2016 to 2018. Of these hospitalizations, 26,465 (9.4%) had a secondary diagnosis of obesity while 255,540 (90.6%) served as controls. IBD hospitalizations with obesity had a higher mean age (47.9 years vs. 45.2 years, P<0.001), middle age (range, 40–65 years) predominance (37.7% vs. 28.9%, P<0.001), female predominance (64.1% vs. 52.5%, P<0.001) and higher proportion of patients with comorbidities compared to the non-obese cohort. White predominance was observed in both subgroups. No difference in the odds of inpatient mortality was noted between the 2 subgroups; however, IBD hospitalizations with obesity had higher mean total hospital charge ($50,126 vs. $45,001, P<0.001), longer length of stay (5.5 days vs. 4.9 days, P<0.001) and higher proportion of complications compared to the non-obese cohort.
Conclusions
Obese IBD hospitalizations had higher length of stay, total hospital charge, and complications compared to the non-obese cohort.

Keyword

Inflammatory bowel disease; Obesity; Epidemiology; Outcomes; Nationwide Inpatient Sample

Reference

1. Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014; 7:113–120.

2. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68(Suppl 3):s1–s106.

3. Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018; 16:26–42.

4. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020; 5:17–30.

5. Centers for Disease Control and Prevention. Facts about IBD [Internet]. c2021 [cited 2021 Mar 13]. https://www.cdc.gov/ibd/data-statistics.htm.

6. Pavelock N, Masood U, Minchenberg S, Heisig D. Effects of obesity on the course of inflammatory bowel disease. Proc (Bayl Univ Med Cent). 2019; 32:14–17.

7. Szilagyi A. Relationship(s) between obesity and inflammatory bowel diseases: possible intertwined pathogenic mechanisms. Clin J Gastroenterol. 2020; 13:139–152.

8. Healthcare Cost and Utilization Project (HCUP). Introduction to the HCUP National Inpatient Sample (NIS), 2018 [Internet]. c2020 [cited 2021 Mar 13]. https://www.hcup-us.ahrq.gov/db/nation/nis/NIS_Introduction_2018.jsp.

9. Healthcare Cost and Utilization Project (HCUP). Nationwide Inpatient Sample (NIS) Redesign Final Report: HCUP Methods Series Report # 2014-04 [Internet]. c2014 [cited 2021 Mar 13]. http://www.hcup-us.ahrq.gov/reports/methods/methods.jsp.

10. Healthcare Cost and Utilization Project (HCUP). Clinical Classifications Software Refined (CCSR) [Internet]. c2021 [cited 2021 Mar 13]. https://hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp.

11. Choi YJ, Choi EK, Han KD, et al. Increased risk of atrial fibrillation in patients with inflammatory bowel disease: a nationwide population-based study. World J Gastroenterol. 2019; 25:2788–2798.

12. Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses- part I. Inflamm Bowel Dis. 2018; 24:742–751.

13. Hammond RA, Levine R. The economic impact of obesity in the United States. Diabetes Metab Syndr Obes. 2010; 3:285–295.

14. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303:235–241.

15. Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017; 14:110–121.

16. Yanovski SZ, Yanovski JA. Obesity prevalence in the United States--up, down, or sideways? N Engl J Med. 2011; 364:987989.

17. Jura M, Kozak LP. Obesity and related consequences to ageing. Age (Dordr). 2016; 38:23.

18. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 20172018. NCHS Data Brief. 2020; (360):1–8.

19. Shah SC, Khalili H, Gower-Rousseau C, et al. Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from Western countries. Gastroenterology. 2018; 155:1079–1089.

20. Shi HY, Levy AN, Trivedi HD, Chan FKL, Ng SC, Ananthakrishnan AN. Ethnicity influences phenotype and outcomes in inflammatory bowel disease: a systematic review and meta-analysis of population-based studies. Clin Gastroenterol Hepatol. 2018; 16:190–197.

21. Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017; 5:161.

22. Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373:1083–1096.

23. D’Souza MJ, Bautista RC, Wentzien DE. Data talks: obesity-related influences on US mortality rates. Res Health Sci. 2018; 3:65–78.

24. Xu F, Wheaton AG, Liu Y, Lu H, Greenlund KJ. Hospitalizations for inflammatory bowel disease among medicare fee-for-service beneficiaries – United States, 1999-2017. MMWR Morb Mortal Wkly Rep. 2019; 68:1134–1138.

25. Johnson AM, Loftus EV Jr. Impact of obesity on the management of inflammatory bowel disease. Gastroenterol Hepatol. 2020; 16:350–359.

26. Seminerio JL, Koutroubakis IE, Ramos-Rivers C, et al. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015; 21:2857–2863.

27. Xu F, Liu Y, Wheaton AG, Rabarison KM, Croft JB. Trends and factors associated with hospitalization costs for inflammatory bowel disease in the United States. Appl Health Econ Health Policy. 2019; 17:77–91.

28. Erlich J, Rubin DT. Predictors of IBD-related length of hospital stay and 30 day readmission in a tertiary center. Am. J Gastroenterol. 2016; 111:S277.

29. Healthcare Cost and Utilization Project (HCUP). NIS description of data elements [Internet]. c2021 [cited 2021 Apr 29]. https://www.hcup-us.ahrq.gov/db/vars/hosp_bedsize/nisnote.jsp.

30. Healthcare Cost and Utilization Project (HCUP). NIS description of data elements: Stratum used to post-stratify hospital [Internet]. c2021 [cited 2021 Apr 29]. https://www.hcup-us.ahrq.gov/db/vars/nis_stratum/nisnote.jsp.

31. Centers for Disease Control and Prevention. Data on obesity [Internet]. c2021 [cited 2021 Mar 13]. https://www.cdc.gov/obesity/data/prevalence-maps.html.

32. Levine JA. Poverty and obesity in the U.S. Diabetes. 2011; 60:2667–2668.